05.07.2012 - Under its FP7 programme, the EU will fund a project with the aim to develop a new blood apheresis device for in vivo trapping of circulating tumour cells (CTC).
The consortium of eleven companies, universities, and research institutes is coordinated by Leon Terstappen, Professor of Medical Cell Biophysics at the University of Twente (MIRA Institute, Netherlands). CTCs detach from a primary tumour and circulate in the bloodstream. They play a crucial role in spreading tumour tissue around a patient’s body. Currently only a small quantity of CTCs can be isolated from blood sample volumes of 7.5 mL for genetic and immune phenotyping to assess the sensitivity of tumour cells towards certain therapeutics. The development project totals EUR9m, of which EUR6m are provided by the EU grant. The German specialist Leukocare will develop an extracorporeal blood apheresis column to filter the patient’s whole blood stream under the roof of the programme. This in vivo trapping will increase the sensitivity of cell counting by about 500-fold. Leukocare will receive a EUR 810,000 contribution from the grant over a period of two years to fund its developmental research.
29.08.2014 Just a week ago, Glaxosmithkline defused the WHO’s claim that an Ebola vaccine could be ready by 2015. Now, the British company’s own candidate vaccine is to be rushed to human trials with the help of funding from an international consortium.
24.08.2014 Germany's Morphosys is licensing a preclinical bi-specific antibody for the treatment of prostate cancer from Emergent Biosolutions. The US developer will rake in up to €138m for the commercialisation rights to the compound.
20.08.2014 Biopharmaceutical contract manufacturer Fujifilm Diosynth Biotechnologies is expanding its cell culture manufacturing capacity further with a new 2,000l single-use bioreactor at the company’s site in Billingham, UK.
08.08.2014 Boehringer Ingelheim is walking away from Swedish Orexo's prostaglandin inhibition project OX-MPI. Germany's largest researching pharmaceutical company had been responsible for the project's research and development since 2005.